The Patent Finder

Immunogenesis, Inc.

8 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Nov 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 19, 2027
    The maintenance fee for TH-302 solid forms and methods related thereto (US 10,654,876) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,003,625Phosphoramidate alkylator prodrugs
In force
 · USPTO record
In forceUSPTO record
US 8,552,048Phosphoramidate alkylator prodrugs for the treatment of cancer
In force
 · USPTO record
In forceUSPTO record
US 8,946,275Treatment of cancer using hypoxia activated prodrugs
In force
 · USPTO record
In forceUSPTO record
US 10,071,109Predictive Biomarker for Hypoxia-Activated Prodrug Therapy
In force
 · High confidence
In forceHigh confidence
US 10,131,683TH-302 solid forms and methods related thereto
In force
 · USPTO record
In forceUSPTO record
US 10,654,876TH-302 solid forms and methods related thereto
In force
 · USPTO record
In forceUSPTO record
US 10,760,130Predictive Biomarker for Hypoxia-Activated Prodrug Therapy
In force
 · High confidence
In forceHigh confidence
US 10,668,047Aziridine containing DNA alkylating agents
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 8: 1 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending

Showing 1 to 2 of 2, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
18/935,071Administration of Hypoxia Activated Prodrugs and Antiangiogenic Agents for the Treatment of CancerNov 1, 2024Pending
18/760,608Compositions Comprising Sting Agonists and Methods of Use for Treating GliomaJul 1, 2024Pending
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited